Rosenstock J, Wysham C, Fras JP, Kaneko S, Lee CJ, Fernndez Land L, Mao H, Cui X, Karanikas CA, Thieu VT
It is not required but is recommended for patients who want objective data on how the protocol is performing, particularly those who are stacking tesamorelin with other peptides targeting metabolic and hormonal goals
Kidney Int 83:517523 Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
Ipamorelin, the first selective growth hormone secretagogue PubMed